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Abstract
In countries where headache services exist at all, their focus is usually on specialist (tertiary) care. This is clinically
and economically inappropriate: most headache disorders can effectively and more efficiently (and at lower cost)
be treated in educationally supported primary care. At the same time, compartmentalizing divisions between
primary, secondary and tertiary care in many health-care systems create multiple inefficiencies, confronting patients
attempting to navigate these levels (the “patient journey”) with perplexing obstacles.
High demand for headache care, estimated here in a needs-assessment exercise, is the biggest of the challenges to
reform. It is also the principal reason why reform is necessary.
The structured headache services model presented here by experts from all world regions on behalf of the Global
Campaign against Headache is the suggested health-care solution to headache. It develops and refines previous
proposals, responding to the challenge of high demand by basing headache services in primary care, with two
supporting arguments. First, only primary care can deliver headache services equitably to the large numbers of
people needing it. Second, with educational supports, they can do so effectively to most of these people. The
model calls for vertical integration between care levels (primary, secondary and tertiary), and protection of the more
advanced levels for the minority of patients who need them. At the same time, it is amenable to horizontal
integration with other care services. It is adaptable according to the broader national or regional health services in
which headache services should be embedded.
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It is, according to evidence and argument presented, an efficient and cost-effective model, but these are claims to
be tested in formal economic analyses.
Keywords: Headache disorders, Public health, Health policy, Barriers to care, Needs assessment, Health-technology
assessment, Structured headache services, Service organization and delivery, Primary care, Global Campaign against
Headache
Introduction
Governments, politicians and health-service managers
concerned about the cost of headache care for very large
numbers of people fail to recognize a fundamentally im-
portant aspect of the economics of headache disorders:
untreated, they are a huge financial drain. The high
levels of disability repeatedly attributed to headache, and
migraine in particular [1–9], are expressed not only as
lost health but also in lost productivity [10–15] and det-
riments to gross domestic product (GDP) [16–19].
In an enlightened view, this is an opportunity. A
wealth of evidence attests the efficacy of treatments for
migraine and other primary headache disorders that can
well be provided by non-specialists [20]. In a reasonable
expectation, good health care delivering these treatments
efficiently to those who will benefit from them will
substantially reduce the ill-health burden of headache.
The costs may be high – because there are very many
such people – but, again in a reasonable expectation, in-
terventions achieving this purpose will be cost-effective
[21]. In many economies they may be cost saving,
through the recovery of lost work time [22].
Regrettably, throughout the world, the opportunity is
missed: health-care systems that ought to provide this
care either do not exist or, where they do, fail to reach
many who need it [23, 24].
In this manuscript, a product of the Global Campaign
against Headache [24–26], we aim to show the solid
basis of these expectations. In so doing, we aim, more
pertinently, to generate political recognition of the need
to address this health-care failure and the educational
failures lying behind it [22]. Further, by setting out a
model of how they can be addressed, we lay the founda-
tions for economic analyses demonstrating the value of
treating headache.
Methods
Experts from all world regions, in headache, health
service organization or health-technology assessment,
were brought together to contribute to these proposals
through email correspondence. The group was diverse,
with members drawn from high-, middle- and low-
income countries.
They took evidence from the published literature and,
using this, built a headache-care model by developing
and refining previous proposals for headache service
organisation [27–29] put forward by Lifting The Burden
(LTB) [26] and the European Headache Federation
(EHF) [30]. They extended the applicability of the model
beyond Europe through their own expertise and local
knowledge and by drawing from experience and under-
standing gained by the Global Campaign against Head-
ache during its 16 years of activities worldwide [26].
The problems
The challenge of numbers
Headache disorders are common, and, although most
are episodic, in many cases they are lifelong conditions.
They are also acknowledged to be among the top three
causes of disability in the world [5–9]. Three – migraine,
tension-type headache (TTH) and medication-overuse
headache (MOH) – account for almost all headache-
attributed burden [1, 5–8]: burden expressed in personal
suffering, disability, impaired quality of life and financial
cost as well as impact extending beyond those immedi-
ately affected [10].
Given all of this, it is unsurprising that large numbers
of people with headache seek health care [31–33]. For
example, in a United Kingdom (UK) study based in
primary care 20 years ago, 17% of registered patients
aged 16–65 years had consulted a general practitioner
(GP) because of headache [33]. This is a good example
because, in the UK, virtually everyone is registered with
a GP.
However, existence of a health disorder, even one that
is manifestly burdensome, does not translate directly
into need for professional health care. Need in the
context of health economics and policy is defined with
regard to potential for benefit. Effective treatments exist
[20, 34], but the proposal that everyone with headache
has need for professional care is not arguable in a
resource-limited world. Need is predicated on antici-
pated benefit, but this must rise above a threshold of
benefit, itself judged against benefit achievable by other
means (cost-effectiveness).
Headache-related health care needs assessment
Thresholds are hard to set objectively, although needs
assessments are highly sensitive to them.
A previous estimate – essentially based on expert
opinion – is that 50% of people with headache can man-
age themselves, using, if necessary, simple over-the-
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counter (OTC) medications [28]. They do not, or rather
should not, need professional health care. While this es-
timate reflects the proportion of successful outcomes in
clinical trials of OTC medications, these have almost all
been conducted in patients, who are not the relevant
denominator.
Many people do manage themselves, a large proportion
through necessity, others from choice, none of them ne-
cessarily effectively. Those who choose self-management
are not only the less severely affected [35]: they include a
number who, for whatever reason and despite significant
disability [36, 37], expect the marginal benefit of profes-
sional involvement in their care to be small (sub-threshold
benefit negates need). Here is a problem, because expecta-
tions are quite often unrealistic – too high, or sometimes
too low – so that needs assessment based on what people
currently do [31–33, 35–47] has very questionable validity.
This is more so when service improvement is planned: a
better service – if “better” means delivering enhanced
benefit – should see greater usage than a poor service it
replaces (discovered need). While planning must factor
this in, it is difficult to estimate.
Aside from these consumer-driven issues, another is
also threshold-dependent. Cash-limited health services
seek value for money: they will discount assessed needs,
however great, whenever utility gain per unit of health-
care resource consumption will be low. In headache
medicine, the potential for benefit from professional
health care is generally greatest among those worst
affected, so that health policy might reasonably focus on
these. Further, both migraine and MOH can, in most
cases, be treated not only effectively but also at rather
low cost [20, 21].
What follows – an assessment of how much profes-
sional headache care should be provided as a matter of
policy – updates earlier estimates [27–29]. The approach
adopted is conservative: it will under- rather than
overestimate need. As will become apparent, any other
approach would be unhelpful.
As with all economic assessments, there are many
assumptions.
The first is that only those with disabling headache
need professional care. The implication that others can
adequately look after themselves is possibly unfair, but
the assumption respects a reasonable view of priority. It
effectively and helpfully removes most people with epi-
sodic TTH from consideration, this disorder generally
(again perhaps unfairly [48]) being regarded as not
significantly disabling [49] (There is also little that
professional care can do for most episodic TTH beyond
offering OTC medications [20]).
About two thirds (66%) of the world’s population are
aged 15–64 years [50], these being the years during
which headache disorders tend to be troublesome.
About 25% are aged 14 or under [51]. Thus, with
regional variations, in every million people living in the
world there are 660,000 and 250,000 in these age groups
respectively. Primary headache is less common, and less
troublesome, in older people [1], who therefore contrib-
ute negligibly to expected numbers.
Best current epidemiological evidence suggests that a
global average of about 15% of adults aged 15–64 have
migraine [1, 6]. Further evidence is that 80% of these
15% (ie, 12%) are significantly disabled through pain and
associated symptoms [52]. In every million people in the
world, therefore, there are 80,000 adults (12% of the
660,000 aged 15–64 years) who need care because of
migraine-attributed disability. A small proportion of
adults have chronic TTH. While this is likely to be
disabling, their numbers are not reliably known, partly
because epidemiological data are limited and partly
because conflation with MOH makes these data unre-
liable. As for MOH, the proportion varies greatly
from country to country, with the best and most re-
cent estimate suggesting a global mean prevalence of
1.5% [53]: another 10,000 (1.5% of the 660,000) need-
ing care for two reasons. MOH is rated as highly dis-
abling [49, 54], not surprisingly since it is frequently
recurring by definition and very painful when present
[55]. Although medication overuse may be the means by
which many people with MOH nonetheless remain
(partly) functional, it always requires professional care
because it will not otherwise resolve.
The total of 90,000 per million (13.5% of the 660,000),
which ignores TTH for reasons stated, is only one third
of the estimated prevalence of all headache including
TTH [1, 6] – substantially less than the 50% proposed
earlier as being the proportion in need of professional
care [28]. It may be over-conservative: it is somewhat
below the UK finding (above) that 17% of GP-registered
adults consult for headache [33], but this, although essentially
a population-based observation, was a reflection of demand,
not need. These, as we argue below, are not the same.
Needs arise in the child and adolescent populations
also, but are more difficult to quantify, partly because
there are fewer data – and none that are reliable in very
young children (below 6 years) [1, 56]. In the age range
6–14 years, headache is apparently as common as in
adults [1, 56, 57], but it has different characteristics.
While migraine prevalence is lower, dependent upon age
and reaching adult levels during the course of adoles-
cence, undifferentiated headache (UdH) largely fills its
place, albeit with less disabling consequences [57].
Furthermore, even migraine in these age groups tends to
be short-lasting. In the absence of better data, a con-
servative but reasonable working basis is that headache-
care needs in these age groups, in terms of numbers, are,
proportionately, half those of adults [28, 29]: another
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17,000 (0.5*13.5% of the 250,000 aged 14 or under) in each
million of the population.
Service provision requirement
From these statistics, with some further assumptions, we
can make arguably fair estimates of service requirements.
First is an assumption about demand. Need and de-
mand overlap, but are not the same – each can exist
without the other. Need for professional headache care,
defined as above (ie, with regard to potential for benefit),
becomes demand only in those who seek care. On the
other hand, care may also be sought in the absence of
need (as defined). Complex and poorly understood fac-
tors govern health-care seeking behaviour and care
utilization by people with headache [35]. On the negative
side are the obstacles to care described below (see The
“patient journey”, and “care pathway”), which act as de-
terrents. Failed self-management is a positive driver.
False expectations – too high or too low - have positive
or negative influences accordingly. Evidence suggesting
that demand for headache care is expressed by as few as
half of those who might be considered in need [33, 35,
36, 58] is unreliable, because studies reporting this were
not well able to judge need for care. Further, it is uncer-
tain whether needs assessment for the purpose of service
provision should reflect needs expression rather than a
more objective assessment of need (as we wrote earlier,
needs assessment based on what people currently do has
very questionable validity). But we will adopt this esti-
mate, pragmatically, because no other exists. If demand
is indeed suppressed by barriers to care, better and more
accessible services, dismantling these barriers, will
generate increase. We assume that take-up of improved
services will still not be 100%, but 75%, representing a
closure of half the currently estimated gap [21].
Second are multiple assumptions about time (Table 1).
These are based on expert views of requirement [21, 28,
29] but tempered with conservatism. They consider only
ambulatory care: inpatient management is ignored in
view of the minimal requirement for it. Admission is
sometimes good practice, because of comorbidities or
for detoxication in MOH, but only in a tiny percentage
of patients.
Notwithstanding the conservatism pervading the as-
sumptions, Table 2 sets out very challenging estimates
of service requirement. We say more about this below
(see The health-care solution).
The failing status quo: inefficient and inequitable services,
and not only in low-income countries
The “patient journey”, and “care pathway”
Evidence from throughout the world is that headache
care reaches a minority of those who need it [22, 35–40]
(to say nothing about its quality).
The primary reason is a worldwide context of low
priority accorded to headache disorders in the queue
for health-care resources, evident for over 20 years [59].
A decade ago, the World Health Organization (WHO)
published its Atlas of Headache Disorders and Re-
sources in the World 2011, recording the worldwide ill
health caused by headache [22]. Noting that this was
mostly untreated, WHO called for change, in a message
distributed to the health ministries of every country
[22]. In the 10 years since, change has not been in
Table 1 Assumptions in estimating service requirements to meet headache-care demand in a population (updated and revised
from [29])
Assumption Argument
The average consultation need per adult patient is 1.25 h per 2 years. This average is within a wide range of variation. In some countries (eg,
Portugal) consultation times are subject to legal recommendations but,
otherwise, consultation need varies mostly according to diagnosis and to
level within the health-care system. Primary-care needs can usually be met
by a first visit of 15–20min’ duration for diagnosis and impact assessment
followed by 10-min visits for monitoring and prescription of acute and pre-
ventative therapies, initially after 2–4 weeks then after each 3–6 months (to-
talling five or six in 2 years). At higher levels of care, first consultations are
usually longer (up to 45min), reflecting case-complexity, but follow-up visits
are fewer.
The average consultation need per child or adolescent patient is
greater: 2 h per 2 years.
Expert opinion cites the need for additional enquiry into family dynamics,
schooling and peer relationships as issues relevant to management success.
No wastage occurs through failures by patients to attend
appointments.
This assumption appears manifestly false, but wastage of this sort is difficult
to predict in the context of proposals for service improvement. At present, it
is commonly discounted by overbooking.
A health-care provider, if working full time on headache without other
clinical responsibilities, is available for consultation for 1380 h/year.a
At any level, 1 day per week is assumed for non-clinical work (administration,
audit and continuing professional development); each week therefore allows
4 days, each of 7.5 h, of patient-contact time. Only 46 weeks are worked per
year.
aThis assumption allows estimates based on full-time equivalence (see Table 2). It is immaterial that full-time commitment to headache is rare except in level 3
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evidence [9, 23], although attention among WHO’s
member states is beginning now to fall on neurological
diseases (including headache) [60].
We estimated above that two thirds of people with
headache could manage themselves, needing no more
than advice from pharmacists [36]. As we will show,
keeping these people out of the health-care system is
crucial to efficient and equitable implementation of care.
But many people who might succeed in self-management
lack the small amount of knowledge on which success
depends, and receive neither educational nor practical
support to help them. Instead, they join the queue for
health care, thus, unnecessarily, embarking upon the
“patient journey”.
The one third who do need professional care are likely
to find the patient journey overcrowded and frustrating,
with headache services fragmentary or difficult to access
and the “care pathway” a mere misnomer – winding and
beleaguered by culs-de-sac and poor signposting [61].
One consequence is direct presentation to emergency
departments, without justifying medical need but bene-
fiting the patient (at high cost) by bypassing the care
pathway altogether [62, 63].
“Headache services”, if existing at all, are too often
equated with headache clinics, usually located sporadic-
ally and in big urban centres according more to market
forces than objective assessment of need. Public
perception is often the driver, encouraged by policies in
many countries that allow direct (and often unguided)
self-referral to specialists. Iran, a country with well-
developed health services, is a good example, with many
people taking fruitless paths to neurosurgeons, otorhino-
laryngologists, ophthalmologists or pain clinics (the
poorly signposted care pathway [61]). In Russia, one in
every three people receiving care for migraine have gone
directly to neurologists [18]. In Estonia, also a country of
the former USSR but with well-developed primary care
and a referral system, the proportion sent by GPs to
neurologists prior to an educational intervention was a
not dissimilar 39.5% [64]. In Western Europe, also one
in three people treated for headache in Spain, and one in
four in Luxembourg, see specialists for this purpose [40].
In Greece, only one fifth of people with headache seek
professional care, but most of these do so from private
neurologists [65]. In the UK, where GPs maintain a gate-
keeper role as an essential feature of the national health
service, the proportion (9%) referred to secondary care
[33] was in line with reasonable expectation (see below:
Division of caseload). Neurologists, however, receiving
most of these referrals, reported that up to a third of all
their patients consulted for headache, more than for any
other neurological condition [31].
Of course, specialist clinics are needed [66], but only
by those with complex disorders requiring high-end
multidisciplinary care, who are a small minority [28, 29].
If specialist clinics with their very limited capacity are at
the centre rather than the apex of headache services, this
purpose is likely to be thwarted by the overload of pa-
tients whose needs should be met elsewhere. Most
people with headache have one of only a few very com-
mon disorders, which ought to be wholly familiar to
primary-care providers and only rarely present diagnos-
tic or management difficulties [20, 28]. But the under-
lying problem is that non-specialist care for headache is
variable at best.
There are illustrative and revealing studies. To begin
in high-income countries [67], in a population-based
study in United States of America (USA) and UK, only
two thirds of adults with migraine were found to be cor-
rectly diagnosed [35]. Half were consulting health-care
providers (HCPs) – too many according to our earlier
(conservative) estimate – but over 60% of those not con-
sulting exhibited high migraine-related disability [35].
There was probable ascertainment bias in this study, but
nonetheless it was indicative of malfunctioning care
pathways in both countries. More recently, the Eurolight
study in 10 European Union (EU) countries found that,
among participants with frequent migraine and an un-
ambiguous need for preventative medication (more than
five headache days per month), fewer than 20% had re-
ceived medical care at any level [68, 69]. Incorporating
indices of adequacy of care, this study identified ad-
equate acute treatment in barely half of these (ie, fewer
than 10% in most of the countries) and even smaller
proportions with the preventative medication for which
they were clearly eligible [40]. In upper-middle-income
Russia [67], again in a population-based survey, only
15% nationwide of people with headache were consult-
ing, one third, as noted, with specialists [18, 41]. In
lower-middle-income Nepal [67], also in a population-
based survey, a much higher 58% of participants with
headache had consulted a professional HCP in the
Table 2 Estimated service requirements to meet headache-related health-care demand in a population of 1 million (from [29])
Estimated numbers expressing demanda Expected demand
Hours/year of medical consultation time FTE health-care providersb required to deliver
Adults: 67,500 (75% of 90,000) 42,200 37
Children and adolescents: 12,750 (75% of 17,000) 12,750 9
FTE Full-time equivalent; aassuming 75% of those with need; bone FTE provider does not necessarily imply one provider engaged full-time on headache; it could,
for example, be two engaged half time on headache, or ten working 10% of full time
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previous year, and 8% had seen a specialist of some sort
[42]. While these findings suggest better availability of
health care in Nepal than in many other, much wealthier
countries (Japan [38] and Taiwan [43], EU countries [40,
44] and UK and North America [35, 45, 46, 52]), all is
not as it seems. The count of “medical consultations” in
Nepal included a very wide range of HCPs, some with
no counterparts or who would not be accredited as
health professionals in other countries [42]. With
pharmacist consultations (15%) excluded, the consulting
proportion fell to 43% [42], similar to the 47% in China
[47]. In the most salient comparison, with only
physician-consultations considered, the proportion fell
further to 19% (GPs 11%, specialists 8% [42]), much
lower than those elsewhere [35, 38, 43, 45–47, 52] – ex-
cept for Russia [18, 41]. Further, since there are no
headache specialists and few neurologists in Nepal,
“specialist” consultations were mostly with ophthalmolo-
gists, otorhinolaryngologists or psychiatrists [42]. In other
words, these findings reflected high demand without
indicating good care: on the contrary, headache-attributed
burden in Nepal remains egregiously high [70].
Educational failures – the root of the problem
The origins of these health-care failures are clearly trace-
able to educational failures, occurring at every level [22].
On the political level, few governments appear willing
to take concerted action against headache [9, 23, 71].
This is puzzling [8, 22]. It indicates a lack of awareness
either of its substantial population ill-health burden (in-
creasingly unlikely, since the Global Burden of Disease
[GBD] study repeatedly affirms this [2–8]) or of its
equally substantial but potentially reversible economic
burdens on society [11–19, 21].
Among HCPs, very limited training in headache [22]
does little to engender interest, good outcomes or, ul-
timately, satisfaction among themselves or their patients.
For doctors this is a problem sewn in medical schools,
the consequence, again, of low priority: worldwide, only
4 h are committed to headache disorders in 4–6 years of
formal undergraduate medical training [22].
Among the general public, headaches – neither fatal
nor contagious, and often invisible – are trivialized as
“normal”, and, far worse, seen by some, in those who
complain of them, as no more than an excuse to avoid
responsibility [23, 72].
All of these need to change.
The health-care solution
The numbers estimated above (see Service provision re-
quirement) cannot be regarded as precise: they are sensi-
tive to the multiple assumptions, particularly those
related to time (Table 1). But, from them, two conclusions
are certain.
First of these is that specialist care, with its very lim-
ited capacity, cannot meet all needs, or even a substan-
tial part of them. Systems or practice that lead to large
numbers of headache referrals to neurologists or other
specialists must be questioned.
Second, and the corollary to this, is that headache care
in the main belongs and must be delivered in primary
care. This is not undesirable for two principal reasons
(others have to do with efficiency and cost containment).
On a neutral level there is, as noted, no clinical objec-
tion to it: education may be required, but the necessary
skills exist in primary care [20, 28]. On the plus side,
since WHO’s Declaration of Alma-Ata of over 40 years
ago [73], wherever health-care reform is in progress
there is emphasis on strengthening primary care, with its
benefits of continuity and care in the community [60,
73–77]. While models of health care vary throughout
the world, whatever the overarching system of care,
primary care has a recognized and important role nearly
everywhere. In highly rural regions, those of sub-
Saharan Africa, for example, primary care in whatever
form it takes is the only point of contact for most
patients.
Structured headache services
Systems approach to health care
Drawing from engineering theory, a systems approach to
a problem or need first identifies it (“understanding the
problem space” – which the foregoing has done) and
then pulls together system elements that, working to-
gether, will resolve the problem or meet the need (“the
solution space”) [78]. There are steps in the process,
working from needs to requirements and from design to
integration to delivery [78], but these do not need to be
detailed here. The key feature shared by all well-
functioning systems – in health care as much as in
engineering – is that “their elements together produce
results not obtainable by the same elements alone” [78].
Applicable particularly to health care, a systems ap-
proach involves “integrating the necessary disciplines
into a team who then use a structured process to deliver
a system” [78]. The health-care solution to headache is
envisioned through applying this approach to headache
care.
Nationwide structured and educationally supported
headache services embedded and integrated within a
country’s health-care system are the means of efficiently,
effectively and equitably mitigating the personal and so-
cietal burdens of headache to the greatest extent possible
with resources available, a proposition put forward by
LTB and endorsed by WHO a decade ago [22]. Struc-
tured headache services pull elements together from
primary, secondary and specialist (tertiary) care, and, im-
portantly, from pharmacy services. Equally importantly,
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they also harness self-management. Educational supports
are an additional element, required at all system levels
and including public education on when and how to
make correct use of these services. Integration within
the broader health-care system is crucial: if headache
services merely develop ad hoc, driven not by coherent
policy but opportunistically by interested individuals, as
is now the case in most countries providing any service
at all, they can be neither efficient nor equitable.
The essential purposes of headache-service organization
are two-fold: to create capacity matched to need, and to
divide service provision rationally between provider levels.
The guiding principle in both purposes is that manage-
ment of patients should be at the lowest level commensur-
ate with good care. Achieving this makes most efficient
use of allocated resources. Basing headache services in
primary care (Fig. 1) extends reach and affords ease of
access [60, 73–77]. Higher levels are reserved for those
with high-frequency, complex or rare headache disorders,
perhaps complicated by comorbidities that require multi-
disciplinary care [28, 29, 66].
A model of headache-service organization
The focus of headache services should be on migraine
and MOH (see above: Headache-related health care
needs assessment [27–29]). This does not exclude other
headache disorders, but TTH, the most prevalent head-
ache, is almost always self-manageable [20, 28, 79] while
other primary headaches are far less common. As for
secondary headaches, their management is of the causa-
tive disorder, and therefore, with a few exceptions (not-
ably MOH), outside the ambit of headache services. But
provision is needed for their recognition, since this is the
responsibility of the services to which affected patients
present – most likely to be headache services when
headache is the symptom.
While organized headache services, if they are to be ef-
ficient and equitable, must be embedded in national or
regional health services, these vary throughout the
world, differently structured and not always adequately
resourced. The model proposed (Fig. 2; Table 3), incorp-
orating three interdependent levels with facilitated but
controlled pathways between them while expanding the
contribution from primary care, is a general guide and
template adaptable to these variations. It is the inter-
ventional model adopted as the health-care solution
to headache by the Global Campaign against Head-
ache [24, 25]. The account here develops and refines
earlier proposals [27–29].
Level 1. General primary care Primary care is the front
line of headache services (Figs. 1 and 2), available locally
and accessible to all who need them. This is not every-
one with headache: the estimated two thirds able to
manage themselves (see above: Headache-related health
care needs assessment) should do so, with advice from
pharmacists and guidance from public educational pro-
grammes built into the model (see below: Educational
implications).
Pharmacy services (perhaps level 0) need to be
highlighted here. They are often greatly underutilized.
Pharmacists are experts in the effects (wanted and un-
wanted) and uses of medications and generally the most
easily accessible of all HCPs. Pharmacists can give guid-
ance and advice not only on self-management but also
on when further professional care should be sought [36].
Level 1 is provided by non-specialist HCPs, not neces-
sarily physicians in a health-care system more dependent
on other practitioners (clinical officers, nurses or com-
munity health workers, for example), although authority
to prescribe is a requirement for non-OTC medications.
Occupational health services can be a helpful adjunct,
Fig. 1 Graphic depiction of headache services organized on three levels, but based in primary care, with predicted caseloads (see text and
Table 3 for explanation). Inset: arguably a better depiction
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Fig. 2 Template for structured headache services supported by educational initiatives, and expected patient flows (adapted and updated from
[26, 27]; see text for explanation)
Table 3 Headache services organized on three levels (from [29], updated from [28])
Level 1. General primary care • front-line headache services (accessible first contact for most people with headache)
• ambulatory care delivered in the community by primary health-care providers (physicians, clinical officers, nurses
and/or community health workers)
• referring when necessary, and (according to setting) acting as gatekeeper, to:
Level 2. Special-interest headache
care
• ambulatory care delivered by physicians, clinical officers or nurses with a special interest and additional training
in headache, in primary or secondary care
• referring when necessary to:
Level 3. Headache specialist
centres
• advanced multidisciplinary care delivered by headache specialists in hospital-based centres
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also provided in proximity to need (especially given the
impact of headache on work). Whatever their back-
ground, HCPs providing level-1 care will need basic
knowledge and understanding of headache disorders for
this purpose, and many will therefore require some
training in headache (see below: Educational implica-
tions). But the model does not require every HCP in
primary care to offer headache services if they can share
caseload between themselves according to their skills
and interests, an arrangement that may be administra-
tively easy in group practices or health centres.
Management aids designed to facilitate non-expert care
are an important support to level 1 [20]. With these and
the educational supports, this level should competently
meet the needs of most people needing professional care
for headache [28, 80]: most cases of migraine (and almost
all of TTH, if needing care) can be diagnosed and man-
aged here by HCPs who should be familiar with recom-
mended acute and preventative drugs [30] and aware of
the constraints in managing fertile women (important
since these are a high proportion of people with migraine).
Cluster headache, MOH and some other common sec-
ondary headache disorders listed in Table 4 should be rec-
ognized but not necessarily managed, and red-flag
warnings of serious secondary headaches should also be
recognized and duly acted upon [20]. Channels for referral
to levels 2 and 3, urgently when necessary, should be in
place for these cases, and for other patients who are diag-
nostically complex or difficult to manage [28, 29].
Level 1 therefore controls flow to higher levels. There
is more to be said about this (see below: The gatekeeper
role within the model).
Finally, this level should continue the long-term care
of patients discharged with treatment plans (as they
should be) from levels 2 or 3 [28, 29, 66, 82].
Level 2. Special-interest headache care Level 2 may be
in primary care, provided by HCPs (usually but not
essentially GPs), but in many countries it is more likely
to be offered in secondary-care polyclinics or district
hospitals and by neurologists (sometimes general physi-
cians, specialists in other fields of internal medicine or
psychiatrists). Either fits the model, with training in
headache to a more advanced but not specialist level
(see below: Educational implications).
Level 2 provides more skilled ambulatory care, and has
capacity only for the relatively small proportion of patients
needing this (Figs. 1 and 2, and see below: Division of case-
load). Competence should embrace the diagnosis and man-
agement of more difficult cases of primary headache, with
experience in using the full range of medications. It should
extend to some secondary headache disorders, though not
those that are very rare [66]. Ideally, HCPs at level 2
should have access to other services such as neuroim-
aging, psychology and physiotherapy. Where this is
not possible, and anyway for the minority of their pa-
tients outside their competence (Table 5), they re-
quire a referral channel to level 3 [28, 29].
To maintain efficiency, level 2 should repatriate
patients to level 1, with management plans, as soon as is
clinically appropriate.
Table 4 ICHD-3 diagnoses [81] to be recognized at level 1 (from [29], updated from [28])
Primary headache disorders Secondary headache disorders
1.1 Migraine without auraa
1.2 Migraine with auraa
1.2.3 Typical aura without headachea
2.1 Infrequent episodic tension-type headachea
2.2 Frequent episodic tension-type headachea
2.3 Chronic tension-type headache
3.1.1 Episodic cluster headache
3.1.2 Chronic cluster headache
5.2.1 Chronic post-traumatic headache attributed to moderate or severe head injury
6.2.2 Headache attributed to subarachnoid haemorrhage
6.4.1 Headache attributed to giant cell arteritis
7.2 Headache attributed to low cerebrospinal fluid (CSF) pressure
7.4.1 Headache attributed to increased intracranial pressure or hydrocephalus caused by neoplasm
8.2 Medication-overuse headachea
9.1 Headache attributed to intracranial infection
10.3 Headache attributed to arterial hypertension
11.3.1 Headache attributed to acute glaucoma
13.1.1 Classical trigeminal neuralgia
aManagement of most of these should be within the competence of level 1
Table 5 Patients likely to be referred to level 3 within optimally
structured headache servicesa (adapted from [29])
Patients with:
• Refractory disabling headache of any type;
• Cluster headache and other trigeminal autonomic cephalalgias, at
first presentation;
• High and low cerebrospinal fluid-pressure headaches;
• Trigeminal and other cranial neuralgias or painful lesions of the
cranial nerves;
• Rare primary or secondary headaches;
• Medication-overuse headache involving drugs of dependence,
where personality mitigates against withdrawal of medication or
where withdrawal attempts have failed;
• Other probable or certain serious secondary headache;
• Headaches with severe physical and/or psychological comorbidities.
Cases of persisting diagnostic uncertainty.
Patients in whom risk of serious underlying disorders demands specialist
investigation.
Patients who may participate in specific level-3 research projects (includ-
ing clinical trials) [66].
adepending in some cases on the facilities and skills available at level 2
Steiner et al. The Journal of Headache and Pain           (2021) 22:78 Page 9 of 23
Level 3. Headache specialist centres Specialized
headache centres sit at the apex of structured headache
services (Fig. 1) [66].
In many countries, they remain an unfulfilled aspir-
ation; in others, they exist – disadvantageously to them
– without the lower levels in place, or are inequitably
distributed. As an example of the last, a survey in Brazil
identified 243 “headache specialists” in 2004/2005. These
were more than twice the number estimated to be
needed for Brazil’s 198 million people [83] in a well-
functioning 3-level system (see below: Division of case-
load), but 68% were in the south-east region catering for
only 42.6% of the country’s population; by contrast,
12.4% were in the north-east for 28.1%, and five of
Brazil’s 27 States had none [84].
The first and foremost role of specialized headache
centres, as tertiary referral centres, is to manage the very
small proportions of patients with primary headache dis-
orders that are especially difficult to diagnose or treat, or
with secondary headaches requiring multidisciplinary
management [81], and those who for other reasons, such
as comorbidities, need specialist intervention [28, 66, 82,
85, 86] (Figs. 1 and 2; Table 5). For this role, they employ
accredited headache specialists or neurologists, and con-
centrate experience in the rare headache disorders and
cranial neuralgias [28, 66]. They have access to equipment
and specialists in other disciplines for the diagnosis and
management of the underlying causes of all secondary
headache disorders [66]. They provide limited but full-
time inpatient facilities (see below: Division of caseload).
Specialized headache centres are therefore situated within
or closely affiliated (with access rights) to a university or
other major hospital [66].
In their second role, level-3 centres support non-
specialists at levels 1 and 2 through clinical advice, train-
ing and development of national management guidelines
[66]. Sustained through bidirectional links, this is a sym-
biotic relationship: well-functioning lower levels reduce
demand on the very limited capacity at level 3. In this
role, level 3 both maintains standards throughout the
system and protects its ability to perform its first role.
Repatriation of patients to level 1 (or 2) as soon as is
clinically appropriate also protects this ability. Again,
this should be with management plans.
Less essential additional roles, including locally mandated
or broader-based research, have been described [66].
Provision for children and adolescents Although their
needs may differ, the model of care is the same for
these age groups, with front-line services (level 1) in
primary care. To the extent that neurological services
provide higher levels of care, these may be replaced
by child neurology or paediatric services. The latter,
in some countries, are better developed than neuro-
logical services.
Division of caseload Quantitative estimates of the pro-
portions of patients with care needs at each level are
largely based on expert opinion [27–29], but with some
empirical support [33]. They shape the model as a
broad-based pyramid with a narrow apex (Fig. 1). As-
suming all levels are in place and functioning efficiently,
they predict 90% managed at level 1 and about 10% at
higher levels, with no more than 1% of all headache
patients at level 3 [28] (Fig. 2).
On these estimates and the earlier assumptions about
consultation times (Table 1), one full-time equivalent
(FTE) HCP at levels 1, 2 or 3 can provide care at those
levels to populations no larger than 25,000, 200,000 and
2 million respectively [28, 29]. (One FTE HCP does not
necessarily imply one engaged full-time in headache ser-
vices; it could, for example, be two HCPs engaged half
time in headache, or ten engaged for 10% of full time.)
For inpatients – the very few with difficult comorbidities,
or with MOH requiring detoxication – a recommended
minimum is two beds per million population [28].
The gatekeeper role within the model The model ex-
pands the role of primary care, and shifts demand in
structured services downwards towards it – a move that
is both clinically appropriate and economically efficient
[60, 73–77]. This brings into focus the gatekeeper role of
primary care as an organizational element of the model
[74, 82, 87–89]. It is a controversial role.
On the one hand, patients cannot be blamed for seek-
ing direct access to perceived experts, and gatekeeping is
not a norm in many countries’ health systems. On the
other, ostensibly, gatekeeping guides patients along the
“care pathway”, efficiently and in their best interests
through the health system according to their needs, not
their demands [87]. This is a well-intentioned purpose,
although arguably somewhat paternalistic. In truth, gate-
keeping is the means of preventing overload in specialist
services, which would deny access to some who really
need it. This is a more defensible consideration. But
gatekeeping is also a means of cost containment, because
specialist care is costly (especially when unnecessary).
Gatekeeping therefore attracts a hostile perception as a
means of rationing [87–89].
How essential is it? Health systems in which gatekeep-
ing is the norm will accommodate it easily within head-
ache services; others may not. More important in all
cases, both to effectiveness of the model [88] and to the
equity of it, is efficiency at the interfaces between levels
(“seams in service continuity” [82, 89]), so that no delays
are system-created against those who do need specialist
care. Efficient interfaces are matters of implementation,
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Table 6 Adaptability of the model according to local requirements and resources (adapted from [29])
Requirement Adaptation
Doctors vs other health-care pro-
viders (HCPs)
Many countries, as policy, are expanding the health-care roles of HCPs other than doctors. Systems in some
countries may depend on service provision at level 1, and perhaps level 2, by clinical officers, nurses and/or com-
munity health workers. This is the way forward, supported by training, if the alternative is nothing.
Primary vs secondary care Level 1 is in primary care. Level 2, on the other hand, can be in primary or secondary care: common options
include neurologists or physicians (trained but non-specialist) in community or district hospitals or polyclinics.
2-level systems Level-3 centres are in secondary care (or tertiary care in countries that make this distinction). Level 3 is therefore
costly and may be unaffordable. When it cannot be fully implemented within this model, or at all, this does not
detract from the benefits that can be provided to the great majority by levels 1 and 2.
Combined levels Level 1 is by its nature community based. It is possible nonetheless, and may be appropriate, for certain level-2
centres also to offer local level-1 care.
Similarly, there is no intrinsic reason why one centre cannot provide both level-2 and level-3 care.
Division of caseload The 90:9:1% split between levels 1, 2 and 3 are estimates of need based largely on expert opinion. Throughout
the world, there are variations in prevalence and characteristics of the common headache disorders, particularly
in the frequency of medication-overuse headache [53]. The division of caseload between levels and capacity at
each level may need adjustment, ideally based on locally gathered empirical data. The model will accommodate
this without fundamental change.
Integration within existing
services
The model adapts equally comfortably to layered and to hub-and-spoke structures, or hybrids of these, according
to a country’s broader health-service structure. It permits bottom-up organization (patient flows driven upwards
by demand at lower levels) or top-down (flows induced upwards by available capacity at higher levels) (Fig. 3).
Fig. 3 Layered (above) and hub-and-spoke (below) structures. The bi-directional arrows indicate patient flows from lower levels to higher, and
clinical and educational supports from higher to lower. Each structure is amenable to top-down or bottom-up organization for integration within
existing health services, although bottom-up is more likely in layered structures and top-down in hub-and-spoke. Hybrid structures are possible
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(placement of levels and
provision of care)
Comments
Abu Dhabi High 3 Layered, bottom-up Level-1 services provided by GPs in
each State-owned primary health-
care centre.
Level-2 services provided either by
GPs in selected primary health-care
centres, or by hospital-based
neurologists.
A single level-3 centre in a specialist
neurology department within a
hospital-based multidisciplinary
health-care facility.
Total population is about 1.5
million. There are 27 State-owned
primary health-care centres, but
500 GPs, many in the private
sector.
Azerbaijan Upper-middle 3 Hybrid system, bottom-up Level-1 services provided in remote
rural areas by GPs in primary care, in
urban areas by GPs in ambulatory-
polyclinic services.
Level-2 services provided either in
the same polyclinics, where so-
called district therapists/GPs can re-
direct to a neurologist (or to level
3), or by neurologists working in pri-
vate clinics or outpatient clinics in
private hospitals.
Level-3 services provided in central
regional hospitals with neurological
beds.
Neurologists at level 2 can
provide clinical and educational
support to GPs in their locality in
a hub-and-spoke arrangement.
Brazil Upper-middle 3 Layered, bottom-up Level-1 services provided in the
community by GPs in primary care.
Level-2 services provided by
neurologists working either in the
community or in hospital-based
secondary care.
Level-3 services provided by
neurological centres, often
university-based, in the larger cities.
Total population is 210 million
(70% covered by public health
services, 25% by supplementary
health services, 5% uncovered),
served by 35,000 GPs, 5000
neurologists and 500 (uncertified)
“headache specialists”. Despite
apparently adequate capacity at
all levels (albeit unevenly
distributed geographically [84]),
fewer than 5% of candidates for
migraine preventative drugs
currently receive them [90].
Bulgaria Upper-middle 3 Layered, bottom-up Level-1 services provided in the
community by GPs in primary care.
Level-2 services provided by
neurologists working either in the
community or in hospital-based
secondary care.
Level-3 services provided by
neurological centres, often
university-based, in the larger cities.
Well-developed primary care
operating a gatekeeper role, but
GPs currently cannot prescribe
many drugs without a specialist
diagnosis.
China Upper-middle 3 Hub and spoke, top down Level-3 services provided by
neurologists in provincial or
university hospitals.
Level-2 services provided by
neurologists in county, district or
municipal hospitals.
Level-1 services provided by GPs in
community health centres or rural
clinics or hospitals.
This system is implemented in
parts of the country [91].
Medical facilities at all levels
provide either Western or
Traditional Chinese medicine.
Colombia Upper-middle 3 Layered, bottom-up Level-1 services provided in the
community by GPs in primary care.
Level-2 services provided by
neurologists in hospital-based
secondary care in intermediate and
larger cities.
Services are overseen by the State
but insurance-based, provided by
multiple private or public com-
panies, each with different
organizations.
Currently, there is a lack of
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(placement of levels and
provision of care)
Comments
Level-3 services provided by
neurological centres, often
university-based, in the larger cities
neurologists, with most located
only in larger cities [92, 93].
Neurological conditions in general
are not a listed priority for the
health-care system [94].
Estonia High 3 Layered, bottom-up Level-1 services provided in the
community by GPs in primary care.
Level-2 services provided by
neurologists working in regional/
county hospitals in private or public
sectors.
Level-3 services provided by a
subspecialty division of a university-
based hospital neurology
department.
Total population is about 1.3
million. There is only one
university-based hospital in the
country, which provides all level-3
services.
Ethiopia Low 2 Layered, bottom-up Level-1 services provided in the
community by community health
workers, nurses, clinical officers and
GPs in rural health posts, local
health centres and primary
hospitals.
Level-2 services provided by GPs,
internists and neurologists working
either in secondary-care general
hospitals in district towns or in
tertiary-care specialized university-
based hospitals in larger cities.
Total population is estimated at




The gatekeeper role can be
effectively integrated into the
existing health-service system by





2 Layered, top down Level-2 services provided by
headache-trained neurologists in
private headache clinics in major
cities.
Level-1 and some level-2 services
provided by GPs or neurologists in
urban health-care facilities elsewhere.
A system of interdependent
private headache clinics currently
operates outside the State system
[95]: there is no State-supported
alternative, and primary care is
poorly developed. Level-3 centres
are aspirational.
Greece High 3 Layered, bottom-up Level-1 services provided by GPs in
private or public health-care sectors.
Level-2 services provided by
neurologists in private or public
settings.
Level-3 centres provided by




Many people with headache are
currently un- or under-treated. A
2018 national general population
survey by the Hellenic Headache
Society (HHS) found that one fifth
seek professional care, most com-
monly from private neurologists [65].
Under the umbrella of HHS there
are, currently, 14 headache
centres in the public sector, three
academic (level 3) [96].
Iceland High 3 Layered, bottom-up Level-1 services provided by GPs in
primary health-care centres.
Level-2 services provided by GPs
with a special interest and
neurologists in district health-care
institutions.
Level-3 services provided by
headache specialists in hospitals
providing specialist services.
Population is 364,000, served by
12 district health-care institutions
and two university or teaching





Lower-middle 3 Hub and spoke, top down A single level-3 centre in the Na-
tional Institute of Mental Health and
Neurosciences (NIMHANS) in
Bangalore.
Level-2 services provided by physicians
with training in headache in affiliated
district or subdistrict hospitals.
Level-1 services provided in urban
areas by GPs in health centres and
State health care is primary (in
community and primary health
centres), secondary (in sub-district
hospitals) and tertiary (in district
hospitals and medical colleges).
Many people favour traditional
remedies.
The hub-and-spoke top-down
system promotes the educational
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(placement of levels and
provision of care)
Comments
in rural areas by medical officers in
community health centres and
primary health centres and by
health workers in subcentres. Where
available, pharmacists may provide
level-1 care.
and clinical supportive roles of the
level-3 centre to levels below.
Iran Upper-middle 3 Layered, bottom-up Level-1 services provided by GPs in
the community or in primary-care
centres.
Level-2 services provided by
neurologists working either in the
community or in hospital-based
secondary care.
Level-3 services provided by
neurological centres, often
university-based, in the larger cities.
Services are supported in
governmental centres and
hospitals, but there are also many
private clinics.
Italy High 3 Layered, bottom-up Level-1 services provided by GPs in
primary care.
Level-2 services provided by
hospital- or clinic-based neurologists
or other specialists with interest in
headache in public or private
sectors.
Level-3 services provided in
academic hospital-based centres by
headache specialists working in
multidisciplinary teams.
Italy’s Health Care System is
national but also regulated at its
21 regional levels. Its population
of 60 million is served by more
than 80 headache and migraine
centres (public, private but
recognized for reimbursement, or
fully private).
National legislation [97] recognizes
chronic primary headache
disorders as disabling and
requiring care.
Mali Low 3 Layered, bottom-up Level-1 services provided by
doctors, nursing assistants and
health technicians in community
health centres.
Level-2 services provided by GPs
and internists, nurses and health
technicians in reference health
centres at district level or in regional
hospitals.
Level-3 services provided by
specialists in national hospitals and
university hospital centres.
Mali’s health services are built on
4 levels in a pyramid structure:
community health centres at level
1 (community); reference health
centres at level 2 (district);
regional hospitals at level 3;
national and university hospitals at
level 4.
In Mali, health systems must
accommodate simultaneous use
of conventional and traditional
medicines to respect long-
established cultural preferences
and practices. Finding the right
formula to integrate these remains
a challenge in health services
generally.
Mongolia Lower-middle 3 Layered, bottom-up Level-1 services provided by GPs in
primary health-care centres or soum
health centres and inter-soum
hospitals.
Level-2 services provided by
neurologists in aimag- or district-
based hospitals.
Level-3 services provided by
neurologists in central State
hospitals.
Aimags are first-level administra-
tive divisions, soums are second-
level. Total population is 3.3 mil-
lion, with primary care services
reaching 70%. Many people favour
traditional remedies.
Level 3 currently is largely
aspirational because of a lack of
headache specialists.
Morocco Lower-middle 3 Hybrid system in public sector
with layered bottom-up and
hub-and-spoke top-down ele-
ments; top-down in private
sector
Level-3 services provided by
neurologists in regional and
university hospitals or in private
hospitals.
Level-2 services provided by
neurologists and GPs with special
interest in district clinics or
provincial hospitals or in private
Morocco has a mix of HCPs:
public (State-sponsored and free)
and private (reimbursed through
insurance or paid out-of-pocket).
Primary care has a gatekeeper
function, which is not always
respected, while access to special-
ists is direct in private care.
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Level-1 services provided by GPs in
public primary health-care centres
or private practices, or, in some rural
areas, by nurses.
Through telemedicine, specialists
in Morocco reach and advise
patients living far from regional
hospitals, a hub-and-spoke system
that can also provide clinical and
educational support to non-










3 Hub and spoke, top down A single level-3 headache centre in
Dhulikhel hospital, Kathmandu Uni-
versity Hospital (DH-KUH).
Level-2 services provided by clinical
officers and/or physicians in DH-
KUH’s outreach health centres.
Level-1 services provided by
community health workers in
outreach primary care centres or
health posts.
Outreach health centres are
around 20 in number in and
around Kavre and adjoining
districts.
Many people favour traditional
remedies.
Countrywide, level 3 is currently
aspirational in a geographically
diverse country with major
accessibility challenges [98] but, in
a population survey, over half of
adults with headache had
engaged with HCPs of varying
sorts [42], indicating capacity to
build on.
Norway High 3 Layered, bottom up Level-1 services provided by GPs in
primary care.
Level-2 services provided by
neurologists (and nurses) working in
hospital-based neurological depart-
ments, or neurologists or GPs with
special interest in headache working
outside hospitals.
Level-3 services provided by
headache specialists and nurses in
academic hospitals, working in
multidisciplinary teams.
A process to establish a national
system for headache care is
commencing now in collaboration
with the Norwegian Ministry of
Health.
Pakistan Lower-middle 3 Hub and spoke, top down Level-3 services provided by
headache-trained neurologists in
private and public tertiary health
centres.
Level-2 services provided by
neurologists in private headache
clinics in larger cities.
Level-1 and some level-2 services
provided by neurologists and GPs in
urban, suburban and rural health-
care facilities and clinics.
Public health-system infrastructure
is fragmented, but both private
and public level-3 services exist in
larger cities. Most adults seeking
headache treatments go first to
GPs, but direct access to special-
ists is available in both public and
private sectors. Therefore, level-1
and level-2 services may currently
be provided by neurologists or
specialists.
A hub-and-spoke top down
model, especially with the use of
telemedicine, can boost education
and support for GPs and remote
practice locations, thereby improv-
ing service structure and reducing
inappropriate demand at level 3.
Perú Upper-middle 3 Layered, bottom-up in public
sector; unstructured in private
sector
Level-1 services provided by GPs,
nurses, nursing assistants and
pharmacists in primary-care health
centres.
Level-2 services provided by
neurologists in regional hospitals
and private clinics.
Level-3 services provided by
specialist accredited neurologists
(neurology services are subdivided
into areas of care, including
headache) in hospitals and institutes
Perú is multicultural, with 31
million population. Its
decentralized health-care system
is administered by five entities
(Ministry of Health, Social Health
Insurance, Armed Forces, National
Police and the private sector) and
suffers from low investment and
lack of horizontal integration.
As in most of Latin America,
headache has low priority. Many
(doctors and general public)
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(placement of levels and
provision of care)
Comments
providing high-complexity care in
departmental capital cities.
believe only neurologists can
resolve it. Structured headache




economic obstacles to transfer of
patients).
Portugal High 3 Layered, bottom up Level-1 services provided by GPs in
primary health-care centres.
Level-2 services provided by
neurologists in referral hospitals
(community hospitals).
Level-3 services provided by
neurologists with specialist training
in headache in central and/or
academic hospitals.
Well-developed occupational
medicine services ally efficiently
and helpfully with community
health services.
Russia Upper-middle 3 Layered, bottom up Level-1 services provided by GPs in
primary health-care centres or
district-based polyclinics.
Level-2 services provided by
neurologists in each regional centre.
Level-3 services provided by
neurologists with specialist training
in headache in each interregional
municipal centre.
Russia has 147 million people, 565,200
physicians, 28,600 neurologists,
> 50 tertiary headache centres
(mostly private) and about 200
“headache specialists” [99]. Up to
half of people with headache
consult a physician, most often a
neurologist, yet fewer than 1% with
migraine use preventative
medications [100]. Russia is only
slowly divesting itself of arcane




nootropic and so-called neuropro-
tector drugs instead of evidence-
based preventative drugs [101].
Ministry of Health
recommendations for
management of migraine [102]
and mandatory inclusion of
headache care in under- and
postgraduate medical education
are addressing care deficiencies
nationally, but a headache-service
implementation project in Sverd-








High 2/3 Layered, bottom up Level-1 services provided by GPs in
primary health centres.
Levels 2 and 3 are hospital-based,
provided by neurologists, some-
times in specialized clinics.
NGHA offers one of Saudi Arabia’s
health-care systems, with two
medical cities, five hospitals and
over 70 primary health-care cen-
tres providing full coverage for
employees and their dependants.
Additionally, it offers services to
the general public for certain dis-
eases and for emergencies (pro-
viding about 50% of their
secondary and tertiary care, to 1.7
million people).
Serbia Upper-middle 3 Layered, bottom up Level-1 services provided by GPs in
public health centres.
Level-2 services provided by
neurologists working either in a
polyclinic system within the same
public health centres or in local
Well-developed primary care with
a gatekeeper role but, currently,
many medications cannot be
prescribed by GPs without
diagnosis by a neurologist, and
many are not reimbursed.
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Level-3 services provided by
specialists in neurological centres,
usually academic, located in the
larger cities.
Turkey Upper-middle 3 Layered, bottom up Level-1 services provided by GPs in
public health centres.
Level-2 services provided by
neurologists in private or
government polyclinics.
Level-3 services provided by
neurologists with specialist training




provides free health insurance to
all but is under-resourced. Not all
drugs are reimbursed, while GPs
in level 1 currently cannot pre-
scribe all medications, and tend to
over-prescribe analgesics. The
consequence is too many patients




High 3 Layered, bottom up Level-1 services provided by GPs in
each practice.
Level-2 services provided by GPs
with special interest (GPwSIs),
sometimes with support from
specialist nurse practitioners, or by
neurologists based in or visiting
district hospitals.
Level-3 centres staffed by specialists,




The gatekeeper role of primary
care is entrenched.
GPwSIs in particular fields are
appointed for local areas with the
purpose of avoiding unnecessary
referrals to specialist care, or by
local commissioning groups as
local or regional leads, or by larger
group practices to take a lead role






High 3 Layered, bottom up Level-1 services provided by primary
care physicians.
Level-2 services provided by
neurologists.
Level-3 services provided by
specialists within neurology
departments, typically in university
settings.
Medicaid (funded jointly by
Federal and State governments
but run by each State separately)
provides free health insurance to
74 million people whose income
and resources are insufficient to
pay for health care. Existing
Federal adult and childhood
quality-of-care measures do not
include headache outcome mea-
sures. Adding these could educate
providers and improve usage of
layered headache care, with better
outcomes expected.
Telemedicine referrals from rural
areas could be employed
between levels 1 and 2 in each
State, and for follow up.
Zambia Lower-middle 3 Layered, bottom up Level-1 services provided in urban
areas in district hospitals by clinical
officers, with or without a physician,
and in rural areas by clinical officers
and community health workers in
community health centres or rural
health posts.
Level-2 services provided by
physicians or clinical officers in
provincial or general hospitals.
Level-3 services provided by
neurologists in the country’s level-3
hospitals (usually university-
affiliated).
These levels correspond with the
3 levels of State-provided health
care, in which clinical officers sub-
stantially outnumber doctors.
Level 3 is only recently a possibil-
ity with the graduation of Zam-
bia’s first adult and paediatric
neurologists. In the near-term,
very small numbers of these spe-
cialists will severely limit level-3
capacity, increasing dependence
on level 2.
GP General practitioner, HCP Health-care provider
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best determined in the context of local health services. If
the model is implemented well, with all levels in place
and adequate provision at each, demand within the levels
is likely to be self-regulating, effectively governed by
waiting lists.
Flexibility of the model Two principal factors
determine how this model might be implemented in a
country (or region or district): the resources allocated to
headache services and the structure of the health service
accommodating them. The model has considerable
flexibility, allowing adaptations in many ways without
altering its intrinsic structure (Table 6).
Table 7 provides illustrations of how, with these adap-
tations, it might be implemented in various countries.
Educational implications Public education has three
main purposes. Firstly, it is needed to improve people’s
understanding of headache. Secondly, it should explain
the use and limitations of OTC medication [79] while
warning against self-mismanagement, the attendant
dangers of medication overuse and the unsupervised
purchase of analgesics from supermarkets and other
unlicensed outlets rather than from pharmacists.
Thirdly, it should explain how to make appropriate
use of headache services, what to expect from them
and, in this context, the likely futility of non-
adherence [105, 106].
WHO identified professional education as the most
pressing requirement in headache services improvement
[22]. Separate educational initiatives are required at each
level. Pharmacists are not generally expected to diag-
nose, having neither the training nor the facilities re-
quired, but they should have the knowledge to recognise
treatment failures and incipient or established medica-
tion overuse [79]. Limited knowledge is required at level
1 [28, 64], but better than usually exists. Enhanced but
still non-specialist knowledge is needed in level 2 [28].
In both, education should be coupled with availability –
and use – of evidence-based guidelines [20, 64, 107, 108]
adapted to local resource availability. Specialist expertise
and competence are expected in level 3, gained through
high-level training and maintained through practice,
continuous professional development and participation
in professional networks (national or international)
allowing exchange of ideas and experience [66]. In the
USA, the United Council for Neurologic Subspecialities
(UCNS) offers examination-based certification (and re-
certification) in headache medicine as a subspecialty
[109], although there is no requirement for a physician
practising as a “headache specialist” to be certified [110].
For some countries, training at this level will require at-
tendance at specialist centres abroad. Several schemes
exist for this. The University of Copenhagen and Danish
Headache Centre, and Sapienza University in Rome,
both offer Master degree courses in headache medicine,
open to students from all countries [111, 112]. Training
scholarships are offered by the International Headache
Society (IHS) [113] and EHF (EHF-SAS [114]).
The major political and logistic implications of
these requirements, especially at level 1 in view of the
numbers of HCPs who need training, are probably
the greatest barrier to nationwide implementation.
Far-reaching national training must be part and parcel
of effective headache-service reform, and it needs to
commence in medical schools. Within the 3-level care
system proposed, a training role for each higher level
towards the level below can be envisaged (Fig. 2).
The entire structure may depend upon these roles be-
ing developed.
A comment on service quality
Effective service implementation does not of itself
guarantee quality of care. Quality-assurance measures
are necessary, as in all fields of medicine.
Standards and indicators exist for headache service
quality evaluation (SQE), developed by LTB specifically
to support implementation of structured headache ser-
vices [108]. They are themselves undergoing evaluation
at the various levels [66, 115–118].
A comment on cost
Headache services delivering care equitably and nation-
wide to large numbers of people will undoubtedly
enhance the headache patients’ journey and improve
outcomes. They will also consume substantial health-
care resources, and require major up-front investment.
Cost-effectiveness becomes a key consideration. While
preliminary economic analyses are highly favourable
[21], there is a cost incurred by doing nothing.
There is promise of even greater savings to offset the
cost – if improvements to services recover the lost
productivity due to headache, or even a small part of it
[11–19, 22]. This promise needs testing in formal eco-
nomic analyses. If it proves to be sound, these savings
foregone as a result of doing nothing become the
financial penalty of inaction [29].
Concluding remarks
Many problems beset the current compartmentalized
division of headache services between primary, second-
ary and tertiary care. The model described seeks vertical
integration. It recognizes that the demand for headache
care dictates delivery for the most part in primary care,
and that this is a perfectly good way forward in terms of
accessibility and effectiveness of care. The model is
amenable to horizontal integration with other care
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services, and capable of adaptation to suit local cultures
and health-care systems.
The need for better – and better resourced – headache
services exists in all countries, differing only quantita-
tively. At a time when momentum is again developing
for health-service reform diverting resources from sec-
ondary to primary care [60, 77], there is opportunity for
change. In low- and middle-income countries in particu-
lar, the growing shift of emphasis in health policy
towards chronic non-communicable diseases [119] creates
a fair climate for change.
Political will, needed for change to happen [9, 22, 60],
will be driven by economic (cost-effectiveness) analyses.
These, so far, have been highly encouraging [21], but
more thorough evaluations are needed.
Abbreviations
EHF: European Headache Federation; EU: European Union; FTE: Full-time
equivalent; GBD: Global burden of disease (study); GDP: Gross domestic
product; GP: General practitioner; HCP: Health-care provider;
ICHD: International classification of headache disorders; IHS: International
Headache Society; LTB: Lifting The Burden; MOH: Medication-overuse
headache; OTC: Over-the-counter; TTH: Tension-type headache;
UdH: Undifferentiated headache; UK: United Kingdom; USA: United States of





TJS, RJ, ZK and LJS developed the model from earlier proposals, with
contributory input from DU, MLi, JO, KP and MTi, as a product of the Global
Campaign against Headache conducted by LTB. All other authors
contributed to its refinement. ZK, LJS, DU, LA, MAlJ, AMAlK, MA, MB, SB, JHE,
RG-G, JBG-G, LSG, AAH, NKa, NKi, GBK, ERL, MLe, OL, YM, IM, DDM, TM, VO,
KP, MFPP, GQ, GNR, AR, ERdlT, DS, MTo, S-YY, MZ, YZZ and JZ-T provided in-
put based on local knowledge and expertise into adaptations of the model
for various countries. TJS drafted the manuscript. All authors contributed to
manuscript revision and approved the final version.
Funding
None.
Availability of data and materials
Not applicable.
Declarations





TJS, RJ, ZK, LJS and DU are the Directors and Trustees of Lifting The Burden.
Otherwise, no author declares a conflict of interest in relation to the content
of this manuscript.
Author details
1Department of Neuromedicine and Movement Science, NTNU Norwegian
University of Science and Technology, Edvard Griegs gate, Trondheim,
Norway. 2Division of Brain Sciences, Imperial College London, London, UK.
3Danish Headache Centre, Department of Neurology, University of
Copenhagen, Rigshospitalet Glostrup, Glostrup, Denmark. 4Evangelical
Hospital Unna, Unna, Germany. 5Department of Neurology, University of
Duisburg-Essen, Essen, Germany. 6EVEX Medical Corporation, Tbilisi, Georgia.
7IM Sechenov First Moscow State Medical University (Sechenov University),
Moscow, Russian Federation. 8Norwegian Advisory Unit on Headache,
Department of Neurology and Clinical Neurophysiology, St Olavs University
Hospital, Trondheim, Norway. 9Neurology Department, Cerrahpaşa School of
Medicine, Istanbul University, Istanbul, Turkey. 10Community Medicine and
Public Health Department, Cadi Ayyad University School of Medicine,
Marrakech, Morocco. 11Department of Neurosciences, King Fahad Medical
City, MOH, Riyadh, Saudi Arabia. 12King Saud Bin Abdulaziz University for
Health Sciences, Riyadh, Saudi Arabia. 13King Abdulaziz Medical City, Riyadh,
Saudi Arabia. 14Headache Clinic, Neurology Clinic, Tartu University Hospital,
Tartu, Estonia. 15Weill Cornell Medicine Headache Program, Department of
Neurology, Weill Cornell Medical College, New York, NY, USA. 16Department
of Neurology, Centralsjukhuset, Kristianstad, Sweden. 17Headache Centre,
Neurology Department, Hospital da Luz, Lisbon, Portugal. 18Hospital de Sant
Joan Despí Moisès Broggi, Barcelona, Spain. 19Faculty of Pharmaceutical
Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
20Department of Anesthesiology, Medical College of Georgia, Augusta
University, Augusta, GA, USA. 21Department of Paediatrics, University
Teaching Hospital, Lusaka, Zambia. 22Laboratory of Clinical and Experimental
Neuroscience, Faculty of Medicine, Université Cadi Ayyad Marrakech,
Marrakech, Morocco. 23Department of Neurology, University Teaching
Hospital Mohammed VI, Marrakech, Morocco. 24Department of Neurology,
National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore,
India. 25Department of Neurology and Neurosurgery, The Ural State Medical
University, Yekaterinburg, Russia. 26International Headache Centre
“Europe-Asia”, Yekaterinburg, Russia. 27Neurology, Public Health, Disability
Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. 28Tjörn
Headache Clinic, Rönnäng, Sweden. 29Department of Neurology, Mongolian
National University of Medical Sciences, Ulaanbaatar, Mongolia. 30Faculty of
Medicine, University of Technical Sciences and Technologies, Bamako, Mali.
31Department of Neurology, University Hospital of Neurology and Psychiatry
“St Naum”, Medical University Sofia, Sofia, Bulgaria. 321st Neurology
Department, Aeginition Hospital, Medical School, National and Kapodistrian
University of Athens, Athens, Greece. 33Chief of Department of Health
Organization, Ministry of Health, Baku, Azerbaijan. 34Moscow Research Clinical
Centre for Neuropsychiatry, Moscow, Russian Federation. 35University
Headache Clinic, Moscow, Russian Federation. 36Department of Neurology,
Ghent University Hospital, Ghent, Belgium. 37Institute of Psychiatry, University
of São Paulo, Hospital Albert Einstein, São Paulo, Brazil. 38Department of
Neurology, Hospital Luis Negreiros Vega, Callao, Lima, Peru. 39Department of
Epidemiology, National Institute of Mental Health and Neurosciences (NIMH
ANS), Bangalore, India. 40Department of Psychiatry, Kathmandu University
School of Medical Sciences (KUSMS), Dhulikhel, Kavre, Nepal. 41Dhulikhel
Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. 42European
Migraine and Headache Alliance, Valencia, Spain. 43Department of Neurology,
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
44Department of Internal Medicine, University Teaching Hospital, Lusaka,
Zambia. 45Neurology Ward, Sina Hospital, School of Medicine, Tehran
University of Medical Sciences, Tehran, Iran. 46Headache Department, Iranian
Center of Neurological Researches, Institute of Neuroscience, Tehran
University of Medical Sciences, Tehran, Iran. 47International Headache Centre,
Department of Neurology, Chinese PLA General Hospital, Beijing, China.
48Department of Neurology, School of Medicine, College of Health Sciences,
Addis Ababa University, Addis Ababa, Ethiopia. 49Neurology Clinic, Clinical
Centre of Serbia, Belgrade, Serbia. 50Care Policy and Evaluation Centre, The
London School of Economics and Political Science, London, UK.
Received: 7 April 2021 Accepted: 25 May 2021
References
1. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher AI, Steiner TJ,
Zwart J-A (2007) The global burden of headache: a documentation of
headache prevalence and disability worldwide. Cephalalgia 27(3):193–210.
https://doi.org/10.1111/j.1468-2982.2007.01288.x
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K,
Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn
SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson
C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez
MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari
Steiner et al. The Journal of Headache and Pain           (2021) 22:78 Page 19 of 23
B, Bikbov B, Bin Abdulhak A et al (2012) Years lived with disability (YLD) for
1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis
for the global burden of disease study 2010. Lancet 380(9859):2163–2196.
https://doi.org/10.1016/S0140-6736(12)61729-2
3. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F,
Davis A, Degenhardt L, Dicker D, Duan L, Erskine H, Feigin VL, Ferrari AJ,
Fitzmaurice C, Fleming T, Graetz N, Guinovart C, Haagsma J, Hansen GM,
Hanson SW, Heuton KR, Higashi H, Kassebaum N, Kyu H, Laurie E, Liang X,
Lofgren K, Lozano R, MacIntyre MF, Moradi-Lakeh M, Naghavi M, Nguyen G,
Odell S, Ortblad K et al (2015) Global, regional, and national incidence,
prevalence, and years lived with disability for 301 acute and chronic
diseases and injuries in 188 countries, 1990–2013: a systematic analysis for
the global burden of disease study 2013. Lancet 386(9995):743–800. https://
doi.org/10.1016/S0140-6736(15)60692-4
4. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016)
Global, regional, and national incidence, prevalence, and years lived with
disability for 310 diseases and injuries, 1990–2015: a systematic analysis for
the global burden of disease study 2015. Lancet 388(10053):1545–1602.
https://doi.org/10.1016/S0140-6736(16)31678-6
5. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F,
Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V, Abu-Raddad
LJ, Ackerman IN, Adamu AA, Adetokunboh O, Afarideh M, Afshin A, Agarwal
SK, Aggarwal R, Agrawal A, Agrawal S, Ahmadieh H, Ahmed MB, Aichour
MTE, Aichour AN, Aichour I, Aiyar S, Akinyemi RO, Akseer N, Al Lami FH,
Alahdab F, Al-Aly Z, Alam K, Alam N, Alam T et al (2017) Global, regional,
and national incidence, prevalence, and years lived with disability for 328
diseases and injuries for 195 countries, 1990-2016: a systematic analysis for
the global burden of disease study 2016. Lancet 390(10100):1211–1259.
https://doi.org/10.1016/S0140-6736(17)32154-2
6. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM,
Ansha MG, Barac A, Bensenor IM, Doan LP, Edessa D, Endres M, Foreman KJ,
Gankpe FG, Gururaj G, Goulart AC, Gupta R, Hankey GJ, Hay SI, Hegazy MI,
Hilawe EH, Kasaeian A, Kassa DH, Khalil I, Khang Y-H, Khubchandani J, Kim
YJ, Kokubo Y, Mohammed MA, Moradi-Lakeh M, Nguyen HLT, Nirayo YL,
Qorbani M, Ranta A, Roba KT et al (2018) Global, regional, and national
burden of migraine and tension-type headache, 1990–2016: a systematic
analysis for the global burden of disease study 2016. Lancet Neurol 17(11):
954–976. https://doi.org/10.1016/S1474-4422(18)30322-3
7. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018)
Global, regional, and national incidence, prevalence, and years lived with
disability for 354 diseases and injuries for 195 countries and territories,
1990–2017: a systematic analysis for the global burden of disease study
2017. Lancet 392:1789–1858
8. GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369
diseases and injuries in 204 countries and territories, 1990–2019: a systematic
analysis for the global burden of disease study 2019. Lancet 396:1204–1222
9. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause
of disability in under 50s: will health politicians now take notice? [editorial]. J
Headache Pain 19(1):17. https://doi.org/10.1186/s10194-018-0846-2
10. Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu SY, Al Jumah
M, Tekle-Haimanot R, Birbeck GL, Herekar A, Linde M, Mbewe E, Manandhar
K, Risal A, Jensen R, Queiroz LP, Scher AI, Wang SJ, Stovner LJ (2014)
Diagnosis, prevalence estimation and burden measurement in population
surveys of headache: presenting the HARDSHIP questionnaire. J Headache
Pain 15(1):3. https://doi.org/10.1186/1129-2377-15-3
11. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999) Burden of
migraine in the United States: disability and economic costs. Arch Intern
Med 159(8):813–818. https://doi.org/10.1001/archinte.159.8.813
12. Selekler MH, Gökmen G, Steiner TJ (2013) Productivity impact of headache
on a heavy-manufacturing workforce in Turkey. J Headache Pain 14(1):88.
https://doi.org/10.1186/1129-2377-14-88
13. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM,
Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée
C (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J
Neurol 19(5):703–711. https://doi.org/10.1111/j.1468-1331.2011.03612.x
14. Raggi A, Leonardi M (2015) Burden and cost of neurological diseases: a
European north-south comparison. Acta Neurol Scand 132(1):16–22. https://
doi.org/10.1111/ane.12339
15. Raggi A, Leonardi M (2020) Burden of brain disorders in Europe in 2017 and
comparison with other non-communicable disease groups. J Neurol
Neurosurg Psychiatry 91(1):104–105. https://doi.org/10.1136/jnnp-2019-320466
16. Steiner TJ, Rao GN, Kulkarni GB, Gururaj G, Stovner LJ (2016) Headache
yesterday in Karnataka state, India: prevalence, impact and cost. J Headache
Pain 17(1):74. https://doi.org/10.1186/s10194-016-0669-y
17. Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, Fang Y, Cao X, He M, Steiner T
(2012) The prevalence and burden of primary headaches in China: a
population-based door-to-door survey. Headache 52(4):582–591. https://doi.
org/10.1111/j.1526-4610.2011.02061.x
18. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G,
Steiner TJ (2014) Headache-attributed burden and its impact on productivity
and quality of life in Russia: structured healthcare for headache is urgently
needed. Eur J Neurol 21(5):758–765. https://doi.org/10.1111/ene.12380
19. Mbewe E, Zairemthiama P, Paul R, Birbeck GL, Steiner TJ (2015) The burden
of primary headache disorders in Zambia: national estimates from a
population-based door-to-door survey. J Headache Pain 16(1):36. https://doi.
org/10.1186/s10194-015-0513-9
20. Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V,
Paemeleire K, Olesen J, Peters M, Martelletti P, on behalf of the European
Headache Federation and Lifting The Burden: the Global Campaign against
Headache (2019) Aids to management of headache disorders in primary
care (2nd edition). J Headache Pain 20:57
21. Linde M, Steiner TJ, Chisholm D (2015) Cost-effectiveness analysis of
interventions for migraine in four low- and middle-income countries. J
Headache Pain 16(1):15. https://doi.org/10.1186/s10194-015-0496-6
22. World Health Organization and Lifting The Burden (2011) Atlas of headache
disorders and resources in the world 2011. WHO, Geneva Available at:
http://www.who.int/mental_health/management/atlas_headache_disorders/
en/2011
23. Katsarava Z, Steiner TJ (2012) Neglected headache: ignorance, arrogance or
insouciance? [editorial]. Cephalalgia 32(14):1019–1020. https://doi.org/10.11
77/0333102412459478
24. Steiner TJ (2004) Lifting the burden: the global campaign against headache.
Lancet Neurol 3(4):204–205. https://doi.org/10.1016/S1474-4422(04)00703-3
25. Steiner TJ (2005) Lifting The Burden: the global campaign to reduce the
burden of headache worldwide. J Headache Pain 6(5):373–377. https://doi.
org/10.1007/s10194-005-0241-7
26. Lifting The Burden. The global campaign against headache. http://www.
l-t-b.org. Accessed 6 June 2021
27. Antonaci F, Valade D, Lanteri-Minet M, Láinez JM, Jensen J, Steiner TJ (2008)
Proposals for the organisation of headache services in Europe. Intern Emerg
Med 3:S25–S28
28. Steiner TJ, Antonaci F, Jensen R, Lainez MJ, Lanteri-Minet M, Valade D (2011)
Recommendations for headache service organisation and delivery in Europe. J
Headache Pain 12(4):419–426. https://doi.org/10.1007/s10194-011-0320-x
29. Steiner TJ, Jensen R, Katsarava Z, Uluduz D, Tinelli M, Thomas H, Stovner LJ
(2019) The healthcare solution to headache. Ch 15. In: Steiner TJ, Stovner LJ
(eds) Societal impact of headache. Burden, costs and response. Springer
Nature, Cham, pp 203–224
30. European Headache Federation. https://ehf-org.org. Accessed 6 June 2021
31. Hopkins A, Menken M, De Friese GA (1989) A record of patient encounters
in neurological practice in the United Kingdom. J Neurol Neurosurg
Psychiatry 52(4):436–438. https://doi.org/10.1136/jnnp.52.4.436
32. Wiles CM, Lindsay M (1996) General practice referrals to a department of
neurology. J Roy Coll Physicians 30:426–431
33. Laughey WF, Holmes WF, MacGregor AE, Sawyer JPC (1999) Headache
consultation and referral patterns in one UK general practice. Cephalalgia
19:328–329
34. Tfelt-Hansen P (2020) Review. Pharmacological strategies to treat attacks of
episodic migraine in adults. Exp Opin Pharmacother 22(3):305–316. https://
doi.org/10.1080/14656566.2020.1828347
35. Lipton RB, Scher AI, Steiner TJ, Kolodner K, Liberman J, Stewart WF (2003)
Patterns of health care utilization for migraine in England and in the United
States. Neurology 60(3):441–448. https://doi.org/10.1212/WNL.60.3.441
36. Mehuys E, Paemeleire K, Van Hees T, Christiaens T, Van Bortel LM, Van
Tongelen I, De Bolle L, Remona J-P, Boussery K (2012) Self-medication of
regular headache: a community pharmacy-based survey. Eur J Neurol 19(8):
1093–1099. https://doi.org/10.1111/j.1468-1331.2012.03681.x
37. Edmeads J (2006) Understanding the needs of migraine patients. Drugs 66:1–8
38. Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, Mori M,
Kawashima M, Kowa H, Adachi Y, Urakami K, Nakashima K (2004)
Population-based door-to-door survey of migraine in Japan: the Daisen
study. Headache 44(1):8–19. https://doi.org/10.1111/j.1526-4610.2004.04004.x
Steiner et al. The Journal of Headache and Pain           (2021) 22:78 Page 20 of 23
39. Radtke A, Neuhauser H (2009) Prevalence and burden of headache and
migraine in Germany. Headache 49(1):79–89. https://doi.org/10.1111/j.152
6-4610.2008.01263.x
40. Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical
care for people with migraine in Europe – evidence from the Eurolight
study. J Headache Pain 19(1):10. https://doi.org/10.1186/s10194-018-0839-1
41. Ayzenberg I, Katsarava Z, Sborowski A, Obermann M, Chernysh M, Osipova
V, Tabeeva G, Steiner TJ (2015) Headache yesterday in Russia: its prevalence
and impact, and their application in estimating the national burden
attributable to headache disorders. J Headache Pain 16(1):7. https://doi.
org/10.1186/1129-2377-16-7
42. Manandhar K, Risal A, Linde M, Steiner TJ (2018) Health-care utilization for
headache disorders in Nepal: a population-based door-to-door survey. J
Headache Pain 19(1):116. https://doi.org/10.1186/s10194-018-0942-3
43. Wang SJ, Fuh JL, Young YH, Lu SR, Shia BC (2001) Frequency and predictors
of physician consultations for headache. Cephalalgia 21(1):25–30. https://doi.
org/10.1046/j.1468-2982.2001.00138.x
44. Lampl C, Buzath A, Baumhackl U, Klingler D (2003) One-year prevalence of
migraine in Austria: a nation-wide survey. Cephalalgia 23(4):280–286. https://
doi.org/10.1046/j.1468-2982.2003.00509.x
45. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF (2002)
Migraine in the United States: epidemiology and patterns of health care
use. Neurology 58(6):885–894. https://doi.org/10.1212/WNL.58.6.885
46. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ
(1993) Impact of migraine and tension-type headache on life-style,
consulting behaviour, and medication use: a Canadian population survey.
Can J Neurol Sci 20(2):131–137. https://doi.org/10.1017/S0317167100047697
47. Liu R, Yu S, He M, Zhao G, Yang X, Qiao X, Feng J, Fang Y, Cao X, Steiner TJ
(2013) Health-care utilization for primary headache disorders in China: a
population-based door-to-door survey. J Headache Pain 14(1):47. https://doi.
org/10.1186/1129-2377-14-47
48. Steiner T, Lange R, Voelker M (2003) Episodic tension-type headache (ETTH):
evidence of prolonged disability from a placebo-controlled comparison of
aspirin and paracetamol. Cephalalgia 23:630
49. Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar
AH, Cassini A, Devleesschauwer B, Kretzschmar M, Speybroeck N, Murray CJ,
Vos T (2015) Disability weights for the global burden of disease 2013 study.
Lancet Glob Health 3(11):e712–e723. https://doi.org/10.1016/S2214-109X(1
5)00069-8
50. World Bank. https://data.worldbank.org/indicator/SP.POP.1564.TO.ZS.
Accessed 6 June 2021
51. World Bank. https://data.worldbank.org/indicator/SP.POP.0014.TO.ZS.
Accessed 6 June 2021
52. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF (2001)
Migraine diagnosis and treatment: results from the American migraine
study II. Headache 41(7):638–645. https://doi.org/10.1046/j.1526-4610.2
001.041007638.x
53. Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH (2014)
Definitions of medication-overuse headache in population-based studies
and their implications on prevalence estimates: a systematic review.
Cephalalgia 34(6):409–425. https://doi.org/10.1177/0333102413512033
54. Togha M, Nadjafi-Semnani F, Martami F, Mohammadshirazi Z, Vahidpour N,
Akbari-sari A, Daroudi R (2020) Economic burden of medication-overuse
headache in Iran: direct and indirect costs. Neurol Sci 42(5):1869–1877.
https://doi.org/10.1007/s10072-020-04716-8
55. Lauwerier E, Paemeleire K, Van Damme S, Goubert L, Crombez G (2011)
Medication use in patients with migraine and medication-overuse
headache: the role of problem-solving and attitudes about pain medication.
Pain 152(6):1334–1339. https://doi.org/10.1016/j.pain.2011.02.014
56. Kyu HH, Pinho C, Wagner JA, Brown JC, Bertozzi-Villa A, Charlson FJ, Coffeng
LE, Dandona L, Erskine HE, Ferrari AJ, Fitzmaurice C, Fleming TD,
Forouzanfar MH, Graetz N, Guinovart C, Haagsma J, Higashi H, Kassebaum
NJ, Larson HJ, Lim SS, Mokdad AH, Moradi-Lakeh M, Odell SV, Roth GA,
Serina PT, Stanaway JD, Misganaw A, Whiteford HA, Wolock TM, Wulf
Hanson S, Abd-Allah F, Abera SF, Abu-Raddad LJ, AlBuhairan FS, Amare AT
et al (2016) Global and national burden of diseases and injuries among
children and adolescents between 1990 and 2013: findings from the global
burden of disease 2013 study. JAMA Pediatr 170(3):267–287. https://doi.
org/10.1001/jamapediatrics.2015.4276
57. Wöber C, Wöber-Bingöl C, Uluduz D, Aslan TS, Uygunoglu U, Tüfekçi A, Alp
SI, Duman T, Sürgün F, Emir GK, Demir CF, Balgetir F, Özdemir YB, Auer T,
Siva A, Steiner TJ (2018) Undifferentiated headache: broadening the
approach to headache in children and adolescents, with supporting
evidence from a nationwide school-based cross-sectional survey in Turkey.
J Headache Pain 19(1):18. https://doi.org/10.1186/s10194-018-0847-1
58. Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R (2005) Secular changes
in health care utilization and work absence for migraine and tension-type
headache: a population based study. Eur J Epidemiol 20(12):1007–1014.
https://doi.org/10.1007/s10654-005-3778-5
59. American Association for the Study of Headache, International
Headache Society (1998) Consensus statement on improving migraine
management. Headache 38(10):736. https://doi.org/10.1046/j.1526-4610.1
998.t01-1-3810736.x
60. World Health Assembly (2020) Synergies in addressing the burden of
epilepsy and other neurological disorders. WHA73_5_en WHO 2020
61. Davies PTG, Lane RJM, Astbury T, Fontebasso M, Murphy J, Matharu M
(2019) The long and winding road: the journey taken by headache sufferers
in search of help. Prim Health Care Res Dev 20:e4. https://doi.org/10.1017/
S1463423618000324
62. Doretti A, Shestaritc I, Ungaro D, Lee J-I, Lymperopoulos L, Kokoti L,
Guglielmetti M, Mitsikostas DD, Lampl C, on behalf of the School of
Advanced Studies of the European Headache Federation (EHF-SAS) (2019)
Headaches in the emergency department –a survey of patients’
characteristics, facts and needs. J Headache Pain 20:100
63. Southwell J, Afridi SK (2021) The burden of migraine on acute and
emergency services in a London teaching hospital. Cephalalgia 18:
333102420981734. https://doi.org/10.1177/0333102420981734 (online ahead
of print)
64. Braschinsky M, Haldre S, Kals M, Iofik A, Kivisild A, Korjas J, Koljal S, Katsarava
Z, Steiner TJ (2016) Structured education can improve primary-care
management of headache: the first empirical evidence, from a controlled
interventional study. J Headache Pain 17(1):24. https://doi.org/10.1186/s101
94-016-0613-1
65. Constantinidis T, Arvaniti A, Fakas N, Rudolf J, Kouremenos E, Giannouli E,
Mitsikostas DD, on behalf of the Hellenic Headache Society (2021) A
population-based survey for disabling headaches in Greece: prevalence,
burden and treatment preferences. Cephalalgia 41(7):810–820. https://doi.
org/10.1177/0333102421989630
66. Steiner TJ, Göbel H, Jensen R, Lampl C, Paemeleire K, Linde M, Braschinsky
M, Mitsikostas D, Gil-Gouveia R, Katsarava Z, on behalf of the European
Headache Federation and Lifting The Burden: the Global Campaign against
Headache (2019) Headache service quality: the role of specialized headache
centres within structured headache services, and suggested standards and
criteria as centres of excellence. J Headache Pain 20:24
67. World Bank (2020) World bank country and lending groups – country
classification. At: https://datahelpdesk.worldbank.org/knowledgebase/a
rticles/906519-world-bank-country-and-lending-groups
68. Andrée C, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lair M-L,
Lanteri-Minet M, Mick G, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Vriezen
P, Lampl C (2011) The Eurolight project: the impact of primary headache
disorders in Europe. Description of methods. J Headache Pain 12(5):541–
549. https://doi.org/10.1007/s10194-011-0356-y
69. Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M,
Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, Andrée C (2014) The
impact of headache in Europe: principal results of the Eurolight project.
J Headache Pain 15(1):31. https://doi.org/10.1186/1129-2377-15-31
70. Manandhar K, Risal A, Linde M, Steiner TJ (2016) The burden of headache
disorders in Nepal: estimates from a population-based survey. J Headache
Pain 17:3
71. Martelletti P, Steiner TJ, Bertolote JM, Dua T, Saraceno B (2007) The
definitive position of headache among the major public health challenges.
An end to the slippery slope of disregard [editorial]. J Headache Pain 8(3):
149–151. https://doi.org/10.1007/s10194-007-0382-y
72. Steiner TJ, Olesen J (2019) Advocacy for patients with headache. Ch 30. In:
Grisold W, Struhal W, Grishold T (eds) Advocacy in neurology. Oxford
University Press, Oxford, pp 339–346
73. World Health Organization International Conference on Primary Health Care
(1978) Declaration of Alma-Ata. WHO, Geneva
74. Tarino E, Webster EG (1995) Primary health care concepts and challenges in
a changing world. Alma-Ata revisited. WHO, Geneva
75. Coulter A (1995) Shifting the balance from secondary to primary care. BMJ
311(7018):1447–1448. https://doi.org/10.1136/bmj.311.7018.1447
Steiner et al. The Journal of Headache and Pain           (2021) 22:78 Page 21 of 23
76. Walley J, Lawn JE, Tinker A, de Francisco A, Chopra M, Rudan I, Bhutta ZA,
Black RE, the Lancet Alma-Ata Working Group (2008) Primary health care:
making Alma-Ata a reality. Lancet 372:1001–1007
77. World Health Organization and United Nations Children’s Fund (UNICEF)
Global Conference on Primary Health Care (2018) Declaration of Astana.
From Alma-Ata towards universal health coverage and the sustainable
development goals. WHO/UNICEF, Astana
78. Clarkson J, Dean J, Ward J, Komashie A, Bashford T (2018) A systems
approach to healthcare: from thinking to practice. Future Healthcare J 5(3):
151–155. https://doi.org/10.7861/futurehosp.5-3-151
79. Haag G, Diener H-C, May A, Meyer C, Morck H, Straube A, Wessely P, Evers S
(2011) Self-medication of migraine and tension-type headache: summary of
the evidence-based recommendations of the Deutsche Migräne und
Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie
(DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the
Schweizerische Kopfwehgesellschaft (SKG). J Headache Pain 12(2):201–217.
https://doi.org/10.1007/s10194-010-0266-4
80. World Health Organization (2000) Headache disorders and public health.
Education and management implications. WHO (WHO/MSD/MBD/00.9),
Geneva
81. Headache Classification Committee of the International Headache Society
(2018) The international classification of headache disorders, 3rd edition.
Cephalalgia 38:1–211
82. Steiner TJ (2003) Health-care systems for headache: patching the seam
between primary and specialist care. J Headache Pain 4(suppl 1):S70–S74
83. Populationpyramid.net. https://www.populationpyramid.net/brazil/2010.
Accessed 6 June 2020
84. Masruha MR, Souza JA, Barreiros H, Piovesan EJ, Kowacs F, Queiroz LP, Ciciarelli
MC, Peres MFP (2007) Distribution of “Brazilian headache specialists”. Analyses
of Brazilian Headache Society members. Einstein 5:48–50
85. Harpole LH, Samsa GP, Jurgelski AE, Shipley JL, Bernstein A, Matchar DB
(2003) Headache management program improves outcome for chronic
headache. Headache 43(7):715–724. https://doi.org/10.1046/j.1526-4610.2
003.03128.x
86. Diener H, Gaul C, Jensen R, Göbel H, Heinze A, Silberstein S (2011)
Integrated headache care. Cephalalgia 31(9):1039–1047. https://doi.org/1
0.1177/0333102411409075
87. Ferris TG, Chang Y, Blumenthal D, Pearson SD (2001) Leaving gatekeeping
behind – effects of opening access to specialists for adults in a health
maintenance organization. NEJM 345(18):1312–1317. https://doi.org/10.1
056/NEJMsa010097
88. Jones R, Lamont T, Haines A (1995) Setting priorities for research and
development in the NHS: a case study on the interface between primary
and secondary care. BMJ 311(7012):1076–1080. https://doi.org/10.1136/
bmj.311.7012.1076
89. Preston C, Cheater F, Baker R, Hearnshaw H (1999) Left in limbo: patients
views on care across the primary/secondary interface. Qual Health Care 8(1):
16–21. https://doi.org/10.1136/qshc.8.1.16
90. Peres MF, Amado DK, Gonçalves AL, Ribeiro R, Pagura JR, Queiroz LP (2011)
The need for preventive therapy in primary headaches. Headache Med 2:
46–49
91. Yu S, Zhang M, Zhou J, Liu R, Wan Q, Li Y (2014) Headache care in China.
Headache 54(4):601–609. https://doi.org/10.1111/head.12330
92. Restrepo Miranda D, Ortiz Monsalve L (2017) Aproximaciones a la
estimación de la oferta y la demanda de médicos especialistas en
Colombia, 2015–2030. Observatorio De Talento Humano En Salud. Retrieved
1 November 2020 from https://www.minsalud.gov.co/sites/rid/Lists/
BibliotecaDigital/RIDE/VS/TH/Especialistas-md-oths.pdf
93. Muñoz Cerón J (2011) A survey about neurology practice in Colombia. Acta
Neurol Colomb 28:180–186 Retrieved 1 November 2020 from http://www.
scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482012000400003
94. Ministerio de Salud y Seguridad Social (2016) Resolución 0256 de 2016.
Boletín Judicial N° 2. Retrieved 1 November 2020 from https://www.minsa
lud.gov.co/Normatividad_Nuevo/Bolet%C3%ADn%20Jur%C3%ADdico%2
0No%202%20Febrero%202016.pdf
95. Giorgadze G, Mania M, Kukava M, Dzagnidze A, Mirvelashvili E, Steiner TJ,
Katsarava Z (2018) Implementation of effective, self-sustaining headache
services in the Republic of Georgia: evaluation of their impact on headache-
related disability and quality of life of people with headache. Cephalalgia
38(4):639–645. https://doi.org/10.1177/0333102417702131
96. Hellenic Headache Society. http://www.kefalalgia.gr/index.php/el/. Accessed
6 June 2021
97. Gazzetta Ufficiale della Repubblica Italiana. LEGGE 14 luglio 2020, n. 81.
Disposizioni per il riconoscimento della cefalea primaria cronica come
malattia sociale. At https://www.gazzettaufficiale.it/eli/id/2020/07/28/20G001
00/SG. Accessed 6 June 2021
98. Risal A, Manandhar K, Steiner TJ, Holen A, Koju R, Linde M (2014) Estimating
prevalence and burden of major disorders of the brain in Nepal: cultural,
geographic, logistic and philosophical issues of methodology. J Headache
Pain 15(1):51. https://doi.org/10.1186/1129-2377-15-51
99. Federal Office for State Statistics, Government of the Russian Federation
(EMISS). Number of doctors of all specialties (individuals) in organizations
providing medical services to the population at the end of the reporting
year. https://www.fedstat.ru/indicator/31547. Accessed 6 June 2021
100. Lebedeva ER, Kobzeva NR, Gilev DV, Olesen J (2017) The quality of diagnosis
and management of migraine and tension-type headache in three social
groups in Russia. Cephalalgia 37(3):225–235. https://doi.org/10.1177/03331
02416642603
101. Osipova VV, Azimova JE, Tabeeva GR, Tarasova SV, Amelin AV, Kutsemelov
IB, Moldovanu IV, Odobesku SS, Naumova GI (2012) Diagnosis of headache
disorders in Russia and in post-Soviet countries: state of the problem and
ways to solve it (in Russian). Ann Clin Exp Neurol 6:16–21
102. Osipova VV, Filatova EG, Artemenko AR, Lebedeva ER, Azimova YY,
Latysheva NV, Sergeev AV, Amelin AV, Koreshkina MI, Skorobogatyh KV,
Ekusheva EV, Naprienko MV, Isaguljan YD, Rachin AP, Danilov AB, Kurushina
OV, Parfenov VA, Tabeeva GR, Gekht AB, Yahno NN (2017) Diagnosis and
treatment of migraine: recommendations of the Russian experts. Zh Nevrol
Psikhiatr Im S S Korsakova 117(1. Vyp. 2):28–42. https://doi.org/10.17116/
jnevro20171171228-42
103. Lebedeva ER, Olesen J, Osipova VV, Volkova LI, Tabeeva GR, Steiner TJ
(2013) The Yekaterinburg headache initiative: an interventional project,
within the global campaign against headache, to reduce the burden of
headache in Russia. J Headache Pain 14(1):101. https://doi.org/10.11
86/1129-2377-14-101
104. UK Department of Health (2003) Guidelines for the appointment of general
practitioners with special interests in the delivery of clinical services:
headaches. Department of Health, London
105. Hedenrud T, Jonsson P, Linde M (2008) Beliefs about medicines and
adherence among Swedish migraineurs. Ann Pharmacother 42(1):39–45.
https://doi.org/10.1345/aph.1K354
106. Mulleners WM, Whitmarsh TE, Steiner TJ (1998) Noncompliance may render
migraine prophylaxis useless, but once-daily regimens are better.
Cephalalgia 18(1):52–56. https://doi.org/10.1046/j.1468-2982.1998.1801052.x
107. Braschinsky M, Haldre S, Kals M, Arge M, Saar B, Niibek M, Katsarava Z,
Steiner TJ (2018) Structured education to improve primary-care
management of headache: how long do the benefits last? A follow-up
observational study. Eur J Neurol 25(3):497–502. https://doi.org/10.1111/
ene.13524
108. Peters M, Jenkinson C, Perera S, Loder E, Jensen R, Katsarava Z, Gil Gouveia
R, Broner S, Steiner T (2012) Quality in the provision of headache care. 2:
defining quality and its indicators. J Headache Pain 13(6):449–457. https://
doi.org/10.1007/s10194-012-0465-2
109. United Council for Neurologic Subspecialities (2020) Headache medicine
certification. https://www.ucns.org/Online/Certification/Headache_Cert.aspx
110. American Headache Society (2020) Tool kit for UCNS headache board
certification. https://americanheadachesociety.org/tool-kit-for-ucns-heada
che-board-certification/
111. University of Copenhagen (2020) Master of Headache Disorders. https://
mhd.ku.dk/
112. Sapienza Università di Roma (2020) Master in Headache Medicine. https://
web.uniroma1.it/masterheadache/
113. International Headache Society (2020) Grants, awards and training
programmes. https://ihs-headache.org/en/resources/grants-awards-and-tra
ining-programmes/
114. European Headache Federation (2020). https://ehf-org.org/educational-a
ctivities/. Accessed 6 June 2021
115. Katsarava Z, Gil Gouveia R, Jensen R, Gaul C, Schramm S, Schoppe A, Steiner
TJ (2015) Evaluation of headache service quality indicators: pilot
implementation in two specialist-care centres. J Headache Pain 16(1):53.
https://doi.org/10.1186/s10194-015-0537-1
Steiner et al. The Journal of Headache and Pain           (2021) 22:78 Page 22 of 23
116. Schramm S, Uluduz D, Gil Gouveia R, Jensen R, Siva A, Uygunoglu U,
Gvantsa G, Mania M, Braschinsky M, Filatova E, Latysheva N, Osipova V,
Skorobogatykh K, Azimova J, Straube A, Emre Eren O, Martelletti P, De
Angelis V, Negro A, Linde M, Hagen K, Radojicic A, Zidverc-Trajkovic J,
Podgorac A, Paemeleire K, De Pue A, Lampl C, Steiner TJ, Katsarava Z (2016)
Headache service quality: evaluation of quality indicators in 14 specialist-
care centres. J Headache Pain 17(1):111. https://doi.org/10.1186/s10194-016-
0707-9
117. Pellesi L, Benemei S, Favoni V, Lupi C, Mampreso E, Negro A, Paolucci M,
Steiner TJ, Ulivi M, Cevoli S, Guerzoni S (2017) Quality indicators in
headache care: an implementation study in six Italian specialist-care centres.
J Headache Pain 18(1):55. https://doi.org/10.1186/s10194-017-0762-x
118. Steiner TJ, Jensen R, Gil-Gouveia R, Katsarava Z (2019) Evaluation: quality in
headache services. Ch 16. In: Steiner TJ, Stovner LJ (eds) Societal impact of
headache. Burden, costs and response. Springer Nature, Cham, pp 225–236
119. World Health Organization (2018) Noncommunicable diseases. http://www.
who.int/news-room/fact-sheets/detail/noncommunicable-diseases
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Steiner et al. The Journal of Headache and Pain           (2021) 22:78 Page 23 of 23
